Verona Pharma

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Verona Pharma excels in COPD trials, secures funding for growth

Verona Pharma's strong performance in Phase 3 trials and solid financial position set a positive trajectory for future growth and NDA submission.
While facing competition and addressing various challenges, the company's strategic vision and upcoming milestones offer opportunities for expansion and partnerships.

Verona Pharma reports strong Q1 earnings, gears up for ensifentrine launch

Verona Pharma's Q1 2023 earnings call highlighted strong financial performance, progress towards NDA submission for ensifentrine, and strategic initiatives for the upcoming launch.
Despite facing challenges in managing expenses and navigating regulatory processes, the company remains optimistic about its market positioning and growth prospects.
With a focus on differentiation, global partnerships, and commercial readiness, Verona Pharma is poised for success in the COPD treatment market in 2024 and beyond.
The company's emphasis on marketing, operational setup, and post-ENHANCE data promotion underscores its commitment to maximizing market impact and revenue potential.

Verona Pharma advances ensifentrine with strong Q2 performance and global expansion prospects

Verona Pharma's Q2 2023 performance showcased progress on ensifentrine and a strong financial position, despite a net loss driven by ongoing expenses.
Strengths include positive trial results, a robust cash position, and global expansion efforts, while challenges lie in financial management and regulatory uncertainties.
Opportunities abound in FDA approval prospects, market expansion through subgroup usage, reimbursement optimization, and product portfolio expansion.
Analysts' inquiries highlighted key concerns and strategic considerations for Verona Pharma's future growth and commercial success in the COPD treatment market.

Verona Pharma advances towards FDA approval with strong financials

Verona Pharma progresses towards FDA approval for ensifentrine, with a set action date.
Financially stable with cash reserves and plans for a robust sales force.
Balancing R&D investments with increased expenses and strategic challenges.
Positioned for growth with pipeline expansion and positive data on treatment impact.

Verona Pharma excels in Q4, eyes FDA approval for ensifentrine

Verona Pharma's Q4 2023 earnings call highlighted strong financials, progress with ensifentrine's FDA submission, and strategic plans for commercial launch and market positioning. While facing challenges in FDA review and commercial strategy, the company remains optimistic about ensifentrine's market prospects and growth opportunities.

Verona Pharma excels in Q1 with ensifentrine progress and financial strength

Verona Pharma's Q1 2024 performance highlighted progress on ensifentrine, strong commercial launch preparations, and a robust financial position.
Strengths lie in ensifentrine's novelty, disease awareness focus, and the company's solid financial foundation.
Challenges include addressing analyst queries, market competition, and ensuring a successful commercial launch.
Opportunities abound in leveraging ensifentrine's utility, financial strength, and the potential for market disruption in COPD treatment.

Verona Pharma reports strong Ohtuvayre sales but faces challenges

Verona Pharma's Q3 2024 earnings call highlighted strong net product sales for Ohtuvayre, but also revealed a net loss after tax. The company's successful launch of Ohtuvayre and progress in new trials and partnerships demonstrate potential for growth. However, Verona Pharma faces challenges in addressing various aspects of its business and potential competition in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Posters highlight ensifentrine’s potential to provide rapid benefits Posters highlight ensifentrine’s potential to provide rapid benefits

Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020

Verona Pharma (VRNA) is developing twice-daily nebulized formulation of ensifentrine as potential maintenance treatment for COPD.

Verona (VRNA) Initiates Pivotal COPD Studies on Ensifentrine

LONDON and RALEIGH, N.C., Sept.  23, 2020  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of its ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) Phase 3 trials to evaluate the efficacy and safety of nebulized ensifentrine in patients with moderate to severe chronic obstructive pulmonary disease (“COPD”).

Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (“MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN.

Intended Delisting and Cancellation of Ordinary Shares from Trading on AIM

LONDON and RALEIGH, N.C., Sept.  17, 2020  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and CEO of Verona Pharma, will ring the Nasdaq stock market closing bell in celebration of the Company’s recent $200 million financing. The virtual ceremony will take place on Monday, September 21, 2020, with formal remarks beginning at 3:45 PM ET.

Verona Pharma to Ring the Nasdaq Closing Bell to celebrate $200 million financing

Publication highlights ensifentrine’s potential to provide rapid symptom relief Publication highlights ensifentrine’s potential to provide rapid symptom relief

Verona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease

LONDON and RALEIGH, N.C., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of a pilot study to investigate the efficacy and safety of ensifentrine delivered via pressurized metered-dose inhaler (“pMDI”) formulation in U.S. patients hospitalized with COVID-19.

Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

LONDON and RALEIGH, N.C., Sept.  02, 2020  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on Monday, September 14, 2020 at 5:00 PM ET.

Verona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference

LONDON and RALEIGH, N.C., Aug.  26, 2020  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that, on August 20, 2020 it granted 6,794,521 Restricted American Depositary Share Units (“RADSUs”), representing 54,356,168 ordinary shares of 5 pence each (“Ordinary Shares”), to directors and employees of Verona Pharma under and in accordance with Verona Pharma’s 2017 Incentive Award Plan (the “Incentive Plan”). In aggregate these RADSU awards are over shares representing 13.11% of the total voting rights in the Company’s current issued share capital (the “TVR”). Details of the Incentive Plan are contained in the Company’s 2019 Annual Report and 20-F SEC filing, both of which are available on the “Investors” section of the Company’s website ( https://www.veronapharma.com/investors/news-sec-filings  ). Additional authority to issue new shares arising from the exercise of options or RADSUs was granted by shareholders at the Company’s most recent annual general meeting held on April 16, 2020.

Verona Pharma plc: Grant of RADSUs and PDMR Dealings

New subgroup analysis supports ensifentrine’s efficacy in symptomatic COPD patients New subgroup analysis supports ensifentrine’s efficacy in symptomatic COPD patients

Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020

Results expected in the first half of 2021 Results expected in the first half of 2021

Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD

Verona Pharma plc (VRNA) CEO David Zaccardelli on Q2 2020 Results - Earnings Call Transcript

The small drugmaker reported good news about new clinical studies for its lead pipeline candidate.

Why Verona Pharma Stock Is Vaulting Higher Today

Completed $200 million private placement post period

Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020

Is  (VRNA) Outperforming Other Medical Stocks This Year?

Has Verona Pharma PLC American Depositary Share (VRNA) Outpaced Other Medical Stocks This Year?

LONDON and RALEIGH, N.C., Aug.  07, 2020  (GLOBE NEWSWIRE) --    

Verona Pharma plc: TR-1: Standard form for notification of major holdings

Norbord

Plantronics

Top Ranked Momentum Stocks to Buy for August 6th 2020

LONDON and RALEIGH, N.C., Aug.  04, 2020  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, notifies the following transactions by persons discharging managerial responsibilities (“PDMRs”).

Verona Pharma plc: Issue of Equity, PDMR Dealings & Total Voting Rights

LONDON and RALEIGH, N.C., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, and Mark Hahn, Chief Financial Officer, will present a company overview at the following virtual investor conferences in August 2020:

Verona Pharma Announces August 2020 Virtual Investor Conference Participation

Asbury Automotive Group

Sprouts Farmers Markets

Simpson Manufacturing

Top Ranked Momentum Stocks to Buy for July 31st

LONDON and RALEIGH, N.C., July  30, 2020  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,  announces that it will report its audited financial results for the three and six months ended June 30, 2020 on Friday, August 14, 2020 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.

Verona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update

As of late, it has definitely been a great time to be an investor of Verona Pharma

Will Verona Pharma Continue to Surge Higher?

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. NEITHER THIS ANNOUNCEMENT, NOR ANYTHING CONTAINED HEREIN, SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION.

Closing of Financing, Issued Share Capital and Total Voting Rights

LONDON, United Kingdom and RALEIGH, N.C., July  17, 2020  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, provides further details regarding the transactions by persons discharging managerial responsibilities (“PDMRs”) in connection with the $200 million Financing announced earlier today.

Verona Pharma plc: PDMR Dealings

Funding to support Phase 3 ENHANCE clinical program in COPD Funding to support Phase 3 ENHANCE clinical program in COPD

News for Verona Pharma Stock (VRNA)